Lombardi Comprehensive Cancer Center
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-21 | NCT04661137 | |
| PRospective Multiple Myeloma Impact Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not applicable | 2026-04-28 | NCT02911571 | |
| Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-03-03 | NCT04091750 | |
| Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid tumor | Recruiting | Not applicable | 2026-01-08 | NCT06980103 | |
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | Enrolling by invitation | Phase 3 | 2022-03-17 | NCT04138927 |